Hospital Pharmacists and the New FDA FAERS Public Dashboard for Cosmetic Products: Expanding Pharmacovigilance into the Cosmetic Safety Landscape. [PDF]
Castellana E, Chiappetta MR.
europepmc +1 more source
Concentration of 226Ra, 232Th and 40K radionuclides in natural products commonly used as cosmetics materials [PDF]
Jamilah Al-Zahrani, Afaf A. Fakeha
openalex
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra +10 more
wiley +1 more source
Correction to "Population-Based Cosmetics Exposure Parameters: Survey Approaches and Cosmetics Usage Results From Different Countries". [PDF]
europepmc +1 more source
Innovative Approaches to Enhancing Formulations and Skin Care Efficacy Through Mesoporous Silica Advancements. [PDF]
Budiman A +6 more
europepmc +1 more source
Regulatory Requirements for the Efficacy/Safety Assessment of Cosmetics/Nano-Cosmetics Products: Opportunities and Challenges for New Approach and Methodologies [PDF]
Aruna Chandran +2 more
openalex +1 more source
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source
Consumer preferences for the development of new emulsion products based on vegetable and animal fats. [PDF]
Kowalska M +5 more
europepmc +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source

